Status I heart transplant patients: conventional versus ventricular assist device support.
Since 1985, 59 United Network for Organ Sharing status I patients have been considered for heart transplantation. Thirty-four patients were supported with drugs and/or intraaortic balloon pump (IABP) (group I). Twenty-five patients were supported with ventricular assist devices (VADs, group II). Forty percent of the patients in each group died before transplantation. Of the 20 group I patients who underwent transplantation, all received inotropic drugs, and five also required IABPs. All 14 group II patients who underwent transplantation were bridged with VADs. No difference was found in age, sex, or cause of disease between the groups. Complications after transplantation were more common in group I. Fourteen group I patients (70%) and 14 group II patients (100%) were discharged from the hospital (p = 0.03). One year after transplantation, mean left ventricular ejection fraction by cardiac catheterization was 53% in group I (12 patients) and 72% in group II (11 patients; p = 0.0008). Although VAD support does not insure transplantation, it strongly favors transplantation survival in status I patients. These data further suggest an advantage of VAD support for long-term survival.
Reedy
J E
JE
Department of Surgery, St. Louis University Medical Center, Mo.
Pennington
D G
DG
Miller
L W
LW
McBride
L R
LR
Lohmann
D P
DP
Noedel
N R
NR
Swartz
M T
MT
D000206:Actuarial Analysis; D000328:Adult; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D005260:Female; D006084:Graft Rejection; D016027:Heart Transplantation / Q000401:mortality*; D006353:Heart-Assist Devices; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007423:Intra-Aortic Balloon Pumping; D007902:Length of Stay; D008297:Male; D011183:Postoperative Complications / Q000453:epidemiology; D011300:Preoperative Care; D012189:Retrospective Studies; D013318:Stroke Volume / Q000502:physiology; D013997:Time Factors
D002316:Cardiotonic Agents; D007166:Immunosuppressive Agents